Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Stock Loses Ground Gained on Yesterday s Novavax Agreement

NEW YORK, Nov. 9 (GenomeWeb News) - Shares in CombiMatrix were down 5.9 percent, or $.12, at $1.91 in mid-afternoon trading after gaining 5.1 percent yesterday on news that it was part of an alliance aimed at monitoring vaccine production.


As GenomeWeb News reported yesterday, CombiMatrix and Novavax plan to develop a technique monitoring vaccine production. Traditional flu-vaccine development and production is too slow to accommodate rapidly evolving flu strains, the company said. CombiMatrix's technique improves the process by tracking the genetic fidelity of the genes encoding the vaccine.


CombiMatrix and Novavax will test the method's efficacy on Novavax's VLP process for producing H5N1 bird flu vaccine.


Financial details were not disclosed.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.